Financhill
Back

Monopar Therapeutics Quote, Financials, Valuation and Earnings

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade
Buy
65

MNPR
Monopar Therapeutics

Last Price:
15.69
Seasonality Move:
4.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!

Monopar Therapeutics Price Quote

$15.69
-0.06 (-8.89%)
(Updated: November 6, 2024 at 4:22 AM ET)

Monopar Therapeutics Key Stats

Buy
65
Monopar Therapeutics (MNPR) is a Buy

Day range:
$15.51 - $16.64
52-week range:
$1.37 - $38.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
9.1%

Volume:
126K
Avg. volume:
1.2M
1-year change:
517.65%
Market cap:
$55.4M
Revenue:
$0
EPS:
$-2.3

How Much Does Monopar Therapeutics Make?

Data Unavailable

Is Monopar Therapeutics Growing As A Company?

Data Unavailable

Monopar Therapeutics Stock Price Performance

What Is Monopar Therapeutics 52-Week High & Low?

Monopar Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Monopar Therapeutics?

Is Monopar Therapeutics Cash Flow Positive?

  • What Is MNPR Cash Flow From Operations?
    Cash flow from operations (TTM) is -$6.8M
  • What Is Monopar Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $3.8M
  • What Is Monopar Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $2M

Monopar Therapeutics Return On Invested Capital

Data Unavailable

Monopar Therapeutics Earnings Date & Stock Price

Monopar Therapeutics Competitors

Monopar Therapeutics Dividend Yield

Monopar Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -11.11%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 18.07
Upside from Last Price: 14.71%

Major Shareholders

  • How many MNPR shares are owned by institutional investors?
    605.2K MNPR shares are owned by institutional investors
  • How many MNPR shares are owned by insiders?
    515K MNPR shares are owned by insiders